IT firm Infosys has announced a definitive agreement to acquire Denmark-based BASE life science, leading technology and consulting firm in the life sciences industry, in Europe.

The acquisition reaffirms the commitment to helping global life sciences companies realise business value from cloud-first digital platforms and data to speed-up clinical trials and scale drug development, positively impacting lives and achieving better health outcomes.

BASE brings to Infosys, domain experts with commercial, medical, digital marketing, clinical, regulatory, and quality know-how. Backed by a team of data science specialists, BASE is at the frontier of the latest technological developments and trends. It has a strong focus on data and AI, and the ability to bridge and integrate business logic and technology, driving insights for better health outcomes.

Together with Infosys, BASE will further expand its portfolio of expertise into consumer health, animal health, medtech and genomics segments. BASE collaborates with leading software technology providers in the life sciences industry such as Veeva, IQVIA and Salesforce. The acquisition is expected to close during the second quarter of fiscal 2023, subject to customary closing conditions.